A61K31/7004

ENTERAL SUSTAINED-RELEASE SUGAR ALCOHOL ADDITIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
20220395009 · 2022-12-15 ·

The present invention relates to an enteral sustained-release sugar alcohol additive including an inner layer structure and an outer layer structure. The inner layer structure contains components of xylitol and agar, and the outer layer structure contains components of carrageenan or gellan gum or xanthan gum or guar gum, vitamin B12, L-arabinose, and fermented bifidobacterium or fermented propionibacterium or fermented lactobacillus. The present invention further provides a method of preparing an enteral sustained-release sugar alcohol additive and an application thereof. In the present invention, by compounding xylitol, L-arabinose and vitamin B12, directional regulation of intestinal microorganisms can be achieved and high concentration synthesis of propionate in the intestine can be realized.

Method of using substrates of AKR1B1/AKR1B10 as anti-cancer drugs

The present disclosure relates to, inter alia, a method of treating cancer in a human patient in need thereof, comprising administering a therapeutically effective amount of a substrate of AKR1B1, AKR1B10, or both to said patient, wherein said patient has, or is suspected to have, cancer cells with elevated levels of AKR1B1, AKR1B10, or both, wherein said substrate is not 2-deoxy-D-glucose.

Method of using substrates of AKR1B1/AKR1B10 as anti-cancer drugs

The present disclosure relates to, inter alia, a method of treating cancer in a human patient in need thereof, comprising administering a therapeutically effective amount of a substrate of AKR1B1, AKR1B10, or both to said patient, wherein said patient has, or is suspected to have, cancer cells with elevated levels of AKR1B1, AKR1B10, or both, wherein said substrate is not 2-deoxy-D-glucose.

Method of using substrates of AKR1B1/AKR1B10 as anti-cancer drugs

The present disclosure relates to, inter alia, a method of treating cancer in a human patient in need thereof, comprising administering a therapeutically effective amount of a substrate of AKR1B1, AKR1B10, or both to said patient, wherein said patient has, or is suspected to have, cancer cells with elevated levels of AKR1B1, AKR1B10, or both, wherein said substrate is not 2-deoxy-D-glucose.

CANCER VACCINE

The invention relates to a combination of a TLR-9 agonist and a conjugate of Formula (I) or pharmaceutically acceptable salt thereof. (Formula (I))

##STR00001##

CANCER VACCINE

The invention relates to a combination of a TLR-9 agonist and a conjugate of Formula (I) or pharmaceutically acceptable salt thereof. (Formula (I))

##STR00001##

TOPICAL COMPOSITION FOR TREATING SKIN WOUNDS
20220378747 · 2022-12-01 ·

A composition for treating skin wounds of an individual is disclosed. The composition is an extract that contains Zinc Gluconate, Lysine, Taurine, Potassium Gluconate, Carboxy Methyl Cellulose, Glycerin, Allantoin, water, Hydrogen chloride (HCl), Lidocaine, Niacin, Valine, L-Isoleucine, Proline, L-Arginine, Threonine, Glutamine, Histidine, Serine, Asparagine, Tyrosine, Cysteine, and pentapeptide for example, Enkephalin. The composition could be applied to the affected skin for effectively treating skin wounds, reducing expression lines, and relaxing muscle contractions, thereby reducing skin wrinkles, and smoothening skin. The composition is provided in at least any one or more forms include a gel, a spray, liquid, lotion, and a cream. The composition maintains a pH balance ranges from about 6.5 to 7.5.

TOPICAL COMPOSITION FOR TREATING SKIN WOUNDS
20220378747 · 2022-12-01 ·

A composition for treating skin wounds of an individual is disclosed. The composition is an extract that contains Zinc Gluconate, Lysine, Taurine, Potassium Gluconate, Carboxy Methyl Cellulose, Glycerin, Allantoin, water, Hydrogen chloride (HCl), Lidocaine, Niacin, Valine, L-Isoleucine, Proline, L-Arginine, Threonine, Glutamine, Histidine, Serine, Asparagine, Tyrosine, Cysteine, and pentapeptide for example, Enkephalin. The composition could be applied to the affected skin for effectively treating skin wounds, reducing expression lines, and relaxing muscle contractions, thereby reducing skin wrinkles, and smoothening skin. The composition is provided in at least any one or more forms include a gel, a spray, liquid, lotion, and a cream. The composition maintains a pH balance ranges from about 6.5 to 7.5.

Multi-nutrient supplement and uses thereof
11590190 · 2023-02-28 · ·

Various embodiments of the invention relate to compositions comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components and methods for using such compositions to treat or prevent diseases associated with oxidative stress, including cardiovascular disease.

Multi-nutrient supplement and uses thereof
11590190 · 2023-02-28 · ·

Various embodiments of the invention relate to compositions comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components and methods for using such compositions to treat or prevent diseases associated with oxidative stress, including cardiovascular disease.